Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bevacizumab + trifluridine/tipiracil hydrochloride|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 11 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|trifluridine/tipiracil hydrochloride||Lonsurf||TAS-102||Lonsurf (trifluridine/tipiracil hydrochloride) is an oral combination comprised of TFT and a thymidine phosphorylase inhibitor, which can result in DNA fragmentation thereby preventing angiogenesis and tumor growth and is FDA approved for use in patients with colorectal cancer, gastric or gastroesophageal junction adenocarcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Bevacizumab + trifluridine/tipiracil hydrochloride||Phase II||Actionable||In a Phase II trial, Avastin (bevacizumab) and Lonsurf (trifluridine/tipiracil hydrochloride) combination treatment resulted in improved progression-free survival (4.6 vs 2.6 months, HR=0.45, p=0.0015) compared to Lonsurf (trifluridine/tipiracil hydrochloride) monotherapy in patients with metastatic colorectal cancer refractory to standard therapies (PMID: 31999946).||31999946|
|Unknown unknown||colorectal cancer||not applicable||Bevacizumab + trifluridine/tipiracil hydrochloride||Phase Ib/II||Actionable||In a Phase I/II trial, Avastin (bevacizumab) and Lonsurf (trifluridine/tipiracil hydrochloride) combination treatment resulted in a 16-week progression-free survival rate of 42.9% (9/21) in patients with metastatic colorectal cancer refractory to standard therapies (PMID: 28760399).||28760399|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02654639||Phase II||Bevacizumab + trifluridine/tipiracil hydrochloride||Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer||Terminated|